Rakefet, Israel

Avidor Shulman

USPTO Granted Patents = 15 

 

Average Co-Inventor Count = 6.1

ph-index = 2

Forward Citations = 17(Granted Patents)


Location History:

  • Rakefet-Doar-Na Misgav, IL (2014)
  • Rakefet, IL (2015 - 2024)

Company Filing History:


Years Active: 2014-2025

Loading Chart...
Loading Chart...
15 patents (USPTO):Explore Patents

Title: Avidor Shulman: Innovator in Biopharmaceuticals

Introduction

Avidor Shulman is a prominent inventor based in Rakefet, Israel. He has made significant contributions to the field of biopharmaceuticals, holding a total of 15 patents. His work focuses on innovative treatments and methodologies that have the potential to impact cancer therapy and genetic disorders.

Latest Patents

Among his latest patents, Shulman has developed methods of use for anti-ILT2 antibodies. This invention provides monoclonal antibodies against ILT2, along with pharmaceutical compositions and methods for producing them. The invention also includes methods for treating cancer by administering these antibodies or compositions. Another notable patent is for stabilized alpha-galactosidase and its uses. This patent describes multimeric protein structures comprising alpha-galactosidase monomers linked via a moiety, which are designed to treat Fabry disease. These structures demonstrate improved performance in terms of enhanced activity and longevity under various conditions.

Career Highlights

Shulman has worked with several notable companies in the biopharmaceutical sector, including Protalix Ltd. and Biond Biologics Ltd. His experience in these organizations has contributed to his expertise in developing innovative treatments and therapies.

Collaborations

Throughout his career, Avidor Shulman has collaborated with talented individuals such as Yoseph Shaaltiel and Ilya Ruderfer. These partnerships have fostered a collaborative environment that encourages innovation and the advancement of biopharmaceutical research.

Conclusion

Avidor Shulman is a distinguished inventor whose work in biopharmaceuticals has led to significant advancements in cancer treatment and genetic disorders. His innovative patents and collaborations highlight his commitment to improving healthcare through scientific research and development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…